

FIȘA DE VERIFICARE

a îndeplinirii standardelor minimale pentru participarea la concursul de ocupare a postului didactic de PROFESOR UNIVERSITAR în cadrul U.M.F. "Carol Davila" din București
Facultatea de Medicină, Facultatea de Farmacie și Facultatea de Moașe și Asistență Medicală

I. Date despre candidat

Nume: Dricu

Prenume: Anica

II. Date numerice privind îndeplinirea standardelor minimale necesare și obligatorii prevăzute în Ordinul Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

1. Articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de autor principal

Criteriul	Standard minim	Realizat
Număr articole ISI <i>in extenso</i> în reviste cotate ISI Web of Science Clarivate, în calitate de autor principal	10	40

Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact, pentru realizarea standardelor minimale.

Nr. Cr t.	Autori	Tip autor prim, contribuție egală, ultim, coresponden	Titlu articol	Revista	An	Volum	Pagini	Factor de impact
-----------	--------	---	---------------	---------	----	-------	--------	------------------

		t si link către revistă sau către documentul scanat in care este menționată explicit contribuția egală sau statutul de autor coresponden t						
AP -1	<u>Semenescu, LE; Kamel, A; Ciubotaru, V; Baez-Rodriguez, SM; Furtos, M; Costachi, A; Dricu, A; Tataranu, LG</u>	Autor corespondent	An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases https://pubmed.ncbi.nlm.nih.gov/37754269/	INTERNATIO NAL JOURNAL OF MOLECULAR SCIENCES	2023	Volume 45 Issue 9 DOI 10.3390/cim b45090485	25	6.2
AP -2	<u>Rodriguez, SMB; Kamel, A; Ciubotaru, GV; Onose, G; Sevastre, AS; Sfredel, V; Danoiu, S; Dricu, A; Tataranu, LG</u>	Autor corespondent	An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma https://pubmed.ncbi.nlm.nih.gov/37446288/	INTERNATIO NAL JOURNAL OF MOLECULAR SCIENCES	2023	Volume2 Issue13 DOI 10.3390/ijms 241311110	24	6.2

AP-3	<u>Rodriguez, SMB; Staicu, GA; Sevastre, AS; Baloi, C; Ciubotaru, V; Dricu, A; Tataranu, LG</u>	Autor corespondent	Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer https://pubmed.ncbi.nlm.nih.gov/35562993/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2022	Volume 23, Issue 9 DOI 10.3390/ijms23094602	19	6.2
AP-4	<u>Sevastre, AS; Baloi, C; Alexandru, O; Tataranu, LG; Popescu, OS; Dricu, A</u>	Ultim autor	The effect of Azo-dyes on glioblastoma cells <i>in vitro</i> https://pubmed.ncbi.nlm.nih.gov/36874201/	SAUDI JOURNAL OF BIOLOGICAL SCIENCES	2022	Volume 30 Issue 3 DOI 10.1016/j.sjbs.2023.103599	11	4.4
AP-5	<u>Sevastre,AS; Manea, EV; Popescu,OS; Tache, DE; Danoiu, S; Sfredel, V; Tataranu, LG; Dricu, A</u>	Ultim autor	Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/36077338/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2022	Volume 23 Issue17 DOI 10.3390/ijms23179943	23	6,2
AP-6	<u>Deleanu, R; Ceafalan, LC; Dricu, A</u>	Ultim autor	Transcriptomic Crosstalk between Gliomas and Telencephalic Neural Stem and Progenitor Cells for Defining Heterogeneity and Targeted Signaling Pathways https://pubmed.ncbi.nlm.nih.gov/34948008/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2022	Volume 22 DOI 10.3390/ijms222413211	23	6,2
AP-7	Sevastre AS, Buzatu IM, Baloi C, Oprita A, Dragoi A, Tataranu LG, Alexandru O,	Ultim autor	ELTD1-An Emerging Silent Actor in Cancer Drama Play. https://pubmed.ncbi.nlm.nih.gov/34068040/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2021	Volume 22(10) doi: 10.3390/ijms22105151	15	6.208

	Tudorache S, Dricu A.							
AP -8	Purcaru OS, Artene SA, Barcan E, Silosi CA, Stanciu I, Danoiu S, Tudorache S, Tataranu LG, Dricu A.	Ultim autor	The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer. https://pubmed.ncbi.nlm.nih.gov/34063231/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES		Volume 22(9) doi: 10.3390/ijms22094830.	15	6.208
AP -9	<u>Alexandru, O;</u> <u>Sevastre, AS;</u> <u>Castro, J;</u> <u>Artene, SA;</u> <u>Tache, DE;</u> <u>Purcaru, OS;</u> <u>Sfredel, V;</u> <u>Tataranu, LG;</u> <u>Dricu, A</u>	Ultim autor	Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines https://pubmed.ncbi.nlm.nih.gov/31547056/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2019	Volume 20 Issue 19 DOI 10.3390/ijms20194663	17	4.556
AP -10	Sevastre, AS; Horescu, C; Baloi, SC; Cioc, CE; Vatu, BI; Tuta, C; Artene, SA; Danciulescu, MM; Tudorache, S; Dricu, A	Ultim autor	Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases. https://www.mdpi.com/2079-6412/9/10/628	COATINGS	2019	Volume 9, Issue10, DOI10.3390/coatings9100628		2.65
AP -11	<u>Artene, SA;</u> <u>Turcu-Stiolica, A;</u> <u>Ciurea, ME;</u> <u>Folcuti, C;</u> <u>Tataranu, LG;</u> <u>Alexandru, O;</u> <u>Purcaru,</u>	Ultim autor	Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials	SCIENTIFIC REPORTS	2018	Volume 8 DOI 10.1038/s41598-018-30296-x	10	4.122

	<u>OS; Tache, DE; Boldeanu, MV; Silosi, C; Dricu, A</u>		https://pubmed.ncbi.nlm.nih.gov/30087385/					
AP-12	<u>Alexandru, O; Purcaru, SO; Tataranu, LG; Lucan, L; Castro, J; Folcuti, C; Artene, SA; Tuta, C; Dricu, A</u>	Ultim autor	The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796178/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2018	Volume 19 Issue 1 DOI 10.3390/ijms19010229	18	4.183
AP-13	Artene SA, Turcu-Stiolica A, Hartley R, Ciurea ME, Daianu O, Brindusa C, Alexandru O, Tataranu LG, Purcaru SO, Dricu A.	Ultim autor	Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. https://pubmed.ncbi.nlm.nih.gov/27877052/	Onco Targets Ther.	2016	Volume 9 doi: 10.2147/OTT.S112842	8	1.653
AP-14	Ciurea ME, Georgescu AM, Purcaru SO, Artene SA, Emami GH, Boldeanu MV, Tache DE, Dricu A	Ultim autor	Cancer stem cells: biological functions and therapeutically targeting.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2014	Volume 9;15(5) doi: 10.3390/ijms15058169.	16	2.339

AP -15	<u>Alexandru, O</u> ; <u>Dragutescu, L</u> ; <u>Tataranu, L</u> ; <u>Ciubotaru, V</u> ; <u>Sevastre, A</u> ; <u>Georgescu, AM</u> ; <u>Purcaru, O</u> ; <u>Danoiu, S</u> ; <u>Bäcklund, LM</u> ; <u>Dricu, A</u>	Ultim autor	Helianthin induces antiproliferative effect on human glioblastoma cells in vitro https://pubmed.ncbi.nlm.nih.gov/20635119/	J Neurooncol	2011	Volume 102 Issue 1 DOI 10.1007/s11060-010-0285-7	9	3.115
AP -16	Carapancea M, Alexandru O, Fetea AS, Dragutescu L, Castro J, Georgescu A, Popa-Wagner A, Bäcklund ML, Lewensohn R, Dricu A.	Ultim autor	Growth factor receptors signaling in glioblastoma cells: therapeutic implications. https://pubmed.ncbi.nlm.nih.gov/19043776/	J Neurooncol	2009	Volum 92(2) doi: 10.1007/s11060-008-9753-8. Epub 2008 Nov 30. PMID: 19043776	10	2.874
AP -17	Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V, Alexandru O, Banita M, Pisoschi C, Bäcklund ML, Lewensohn R, Dricu A.	Ultim autor	Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. https://pubmed.ncbi.nlm.nih.gov/17568996/	J Neurooncol.	2007	Volum 85(3) doi: 10.1007/s11060-007-9417-0. Epub 2007 Jun 14. PMID: 17568996	9	1.881

AP-18	Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabeto M, Kanter L, Lewensohn R, Dricu A.	Ultim autor	Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. 1-8. PMID: 17454144	Growth Factors	2007	Volum 25(1) doi: 10.1080/08977190600702865.	8	4.177
AP-19	Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A.	Ultim autor	Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism.	Oncogene	2007	Volum 12;26(17) doi: 10.1038/sj.onc.1210037. Epub 2006 Oct 9. PMID: 17043647	11	6.44
AP-20	Dricu A , Carlberg M, Wang M, Larsson O.	Prim autor	Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis.	Cancer Res.	1997	Volum 1;57(3):543-8 PMID: 9012488		8,206

21. Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). Sevastre AS, Costachi A, Tataranu LG, Brandusa C, Artene SA, Stovicek O, Alexandru O, Danoiu S, Sfredel V, Dricu A. *Exp Ther Med.* 2021 Dec;22(6):1408. doi: 10.3892/etm.2021.10844. Epub 2021 Oct 6. PMID: 34676001. Autor Principal IF=2.751
22. Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities. Dricu A. *Int J Mol Sci.* 2022 Jul 2;23(13):7376. doi: 10.3390/ijms23137376. PMID: 35806381 Free PMC article. Autor Principal IF=5.6
23. Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A, Dricu A. *Contemp Oncol (Pozn).* 2020;24(1):55-66. doi: 10.5114/wo.2020.94726. Epub 2020 Mar 30. PMID: 32514239 Free PMC article. Review. Autor Principal
24. The Role of Imaging Techniques in Diagnosing Pancreatic Cancer. Sas, L (Sas, Lorena) [1]; Taisescu, O (Taisescu, Oana) [1]; Taisescu, CI (Taisescu, Citto Iulian) [2]; Artene, SA (Artene, Stefan-Alexandru) [4]; Dumitra, G (Dumitra, Gindrovel) [5]; Tudorache, S (Tudorache, Stefania) [6]; Dricu, A (Dricu, Anica) [4]; Sas, T (Sas, Teodor) [3], *REVISTA DE CHIMIE* Volume70 Issue5 Page 1608-1614 Published MAY 2019 Autor Principal IF=1.755

25. Accuracy of Imaging Investigations in Pancreatic Cancer Diagnosis. Sas, L (Sas, Lorena) [1]; Taisescu, O (Taisescu, Oana) [1]; Artene, SA (Artene, Stefan-Alexandru) [2]; Dricu, A (Dricu, Anica) [2]; Sas, T (Sas, Theodor) [3]; Gindrovel, D (Gindrovel, Dumitra) [4]; Taisescu, CI (Taisescu, Citto Iulian) [5] REVISTA DE CHIMIE, Volume 70, Issue 4 Page1272-1277 Published APR 2019. Autor Principal IF=1.755
26. *In vitro* Antineoplastic Activity of Dye Compounds on Human Glioblastoma Cells Alexandru, O (Alexandru, Oana) [1]; Georgescu, AM (Georgescu, Ada Maria) [1]; Dragoi, A (Dragoi, Alexandra) [1]; Ciurea, ME (Ciurea, Marius Eugen) [2]; Taisescu, CI (Taisescu, Citto Iulian) [1]; Tataranu, LG (Tataranu, Ligia Gabriela) [3]; Brindusa, C (Brindusa, Corina) [1]; Boldeanu, MV (Boldeanu, Mihai Virgil) [4]; Purcaru, SO (Purcaru, Stefana Oana) [1]; Silosi, CA (Silosi, Cristian Adrian) [5]; Demetrian, A (Demetrian, Alin) [6]; Dricu, A (Dricu, Anica) [1] REVISTA DE CHIMIE (provided by Clarivate) Volume 70, Issue1 Page112-117 Published JAN 2019 Autor Principal IF=1.755
27. coRibavirin-induced Anemia in Patients with Chronic Hepatitis C Virus Infection. Taisescu, CI (Taisescu, Citto Iulian) [1]; Demetrian, A (Demetrian, Alin) [2]; Biciusca, V (Biciusca, Viorel) [3]; Dricu, A (Dricu, Anica) [4]; Artene, SA (Artene, Stefan Alexandru) [4]; Cioc, C (Cioc, Catalina) [4]; Taisescu, O (Taisescu, Oana) [5] REVISTA DE CHIMIE Volume 69. Issue12Page3648-3652DEC 2018. Autor Principal IF=1.412
28. Recent challenges with stem cell banking. Dricu A. Expert Opin Biol Ther. 2018 Apr;18(4):355-358. doi: 10.1080/14712598.2018.1445715. Epub 2018 Feb 26. PMID: Autor Principal IF=3.974
29. *LIGUSTRUM VULGARE* HYDROALCOHOLIC EXTRACT INDUCES APOPTOTIC CELL DEATH IN HUMAN PRIMARY BRAIN TUMOUR CELLS Tataranu, LG (Tataranu, Ligia Gabriela) [1]; Georgescu, AM (Georgescu, Ada Maria); Buteica, SA (Buteica, Sandra Alice); Silosi, I (Silosi, Isabela; Mogosanu, GD (Mogosanu, George Dan) [5]; Purcaru, SO (Purcaru, Stefana Oana) [2]; Alexandru, O (Alexandru, Oana); Stovicek, OP (Stovicek, Olivian Puiu); Brindusa, C (Brindusa, Corina); Dosa, M (Dosa, Monica); Taisescu, CI (Taisescu, Citto Iulian); Dricu, A (Dricu, Anica) 2017 FARMACIA Volume 65 Issue 5 Page 766-771 Autor Principal IF=1.507
30. The effect of curcumin on low-passage glioblastoma cells in vitro. Alexandru O, Georgescu AM, Ene L, Purcaru SO, Serban F, Popescu A, Brindusa C, Tataranu LG, Ciubotaru V, Dricu A. J Cancer Res Ther. 2016 Apr-Jun;12(2):1025-32. doi: 10.4103/0973-1482.167609. PMID: 27461692 Autor Principal IF=1.791
31. New perspectives in glioblastoma antiangiogenic therapy. Popescu AM, Purcaru SO, Alexandru O, Dricu A. Contemp Oncol (Pozn). 2016;20(2):109-18. doi: 10.5114/wo.2015.56122. Epub 2015 Dec 8. PMID: 27358588 Free PMC article. Review. Autor Principal
32. Rationale and *in vitro* efficacy of *Ligustrum vulgare* hydroalcoholic extract for the treatment of brain tumors, Mogosanu, GD (Mogosanu, George Dan) [1]; Buteica, SA (Buteica, Sandra Alice) [2]; Purcaru, SO (Purcaru, Stefana Oana) [3]; Croitoru, O (Croitoru, Octavian) [2]; Georgescu, AM (Georgescu, Ada Maria) [3]; Serban, F (Serban, Florentina) [3]; Tataranu, LG (Tataranu, Ligia Gabriela) [4]; Alexandru, O (Alexandru, Oana) [3]; Dricu, A (Dricu, Anica) 2016. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY Volume 9. Issue 8. Page 8286-8296 Autor Principal IF=1.706
33. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. Serban F, Artene SA, Georgescu AM, Purcaru SO, Tache DE, Alexandru O, Dricu A. Onco Targets Ther. 2015 Dec 16;8:3767-74. doi: 10.2147/OTT.S93843. eCollection 2015. PMID: 26719704 Free PMC article. Review. Autor Principal IF=2.272
34. Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Popescu AM, Alexandru O, Brindusa C, Purcaru SO, Tache DE, Tataranu LG, Taisescu C, Dricu A. Int J Clin Exp Pathol. 2015 Jul 1;8(7):7825-37. eCollection 2015. PMID: 26339347 Free PMC article. Autor Principal IF=1.581
35. Biobanking in a constantly developing medical world. Artene SA, Ciurea ME, Purcaru SO, Tache DE, Tataranu LG, Lupu M, Dricu A. ScientificWorldJournal. 2013 Sep 23;2013:343275. doi: 10.1155/2013/343275. eCollection 2013. PMID: 24174912 Free PMC article. Review. Autor Principal IF=1.219
36. S-Adenosylmethionine - induced cytotoxicity in glioblastoma cells does not affect the Igf-1r methylationOla, R (Ola, Roxana) [2], [3]; Scorei, ID (Scorei, Iulia D.) [1]; Neagoe, IB (Neagoe, Ioana Berindan) [3], [4]; Balacescu, O (Balacescu, Ovidiu) [4]; Banicioiu, M (Banicioiu, Mihai) [1]; Dricu, A (Dricu, Anica). 2010. REVISTA ROMANA DE MEDICINA DE LABORATOR . Volume 18. Issue 3 Page 51-59 Autor Principal IF=0.113

37. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, Dricu A. Cancer Lett. 2005 May 26;222(2):173-81. doi: 10.1016/j.canlet.2004.10.002. Epub 2004 Nov 11. PMID: 15863266 Autor Principal IF=3.049
38. A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. Dricu A, Sergiu-Bogdan C, Brismar K, Biberfeld P, Andersson LC. Anticancer Res. 2004 May-Jun;24(3a):1427-32. PMID: 15274305 Free article. Autor Principal IF=1.395
39. Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Dricu A, Kanter L, Wang M, Nilsson G, Hjertman M, Wejde J, Larsson O. Glycobiology. 1999 Jun;9(6):571-9. doi: 10.1093/glycob/9.6.571. PMID: 10336989 IF=3.728
40. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O. Glycobiology. 1997 Jul;7(5):625-33. doi: 10.1093/glycob/7.5.625. PMID: 9254045 IF=2.927
41. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Dricu A, Carlberg M, Wang M, Larsson O. Cancer Res. 1997 Feb 1;57(3):543-8. PMID: 9012488 IF=8.426

Criteriu îndeplinit:

DA NU

2. Articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de coautor

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de coautor	5	17

Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact, pentru realizarea standardelor minime.

Nr. Crt	Autori	Titlu articol	Revista	An	Volum	Pagini	Factor de impact
.							

CA -1	<u>Semenescu, LE; Tataranu, LG; Dricu, A; Ciubotaru, GV; Radoi, MP; Rodriguez, SMB); Kamel, A.</u>	A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis https://www.mdpi.com/2227-9059/11/9/2485	BIOMEDICINES	2023	Volume 11 Issue 9 DOI 10.3390/biomedicines11092485	18	5.6
CA -2	<u>Isabela Siloși , Lidia Boldeanu , Viorel Biciușcă , Maria Bogdan Carmen Avramescu , Citto Taisescu , Vlad Padureanu , Mihail Virgil Boldeanu , Anica Dricu , Cristian Adrian Siloși</u>	Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/28629188/	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2017	Volume 18 Issue 6 DOI 10.3390/ijms18061304	10	3.257
CA -3	<u>Budiu, RA; Diaconu, I; Chrissluis, R; Dricu, A; Edwards, RP; Vlad, AM</u>	A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+regulatory T cells https://pubmed.ncbi.nlm.nih.gov/19841240/	DISEASE MODELS & MECHANISMS	2009	Volume2 Issue 11-12 Page 593-603 DOI 10.1242/dmm.002535	10	3.304
CA -4	<u>Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, Lundeberg J, Wejde J, Bartolazzi A, Wiman KG, Larsson O.</u>	Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. https://pubmed.ncbi.nlm.nih.gov/11016658/	Cancer Res.	2000	Volume 60(18) PMID: 11016658	5	8,46

CA-5	Catrina SB, Lewitt M, Massambu C, Dricu A, Grünler J, Axelson M, Biberfeld P, Brismar K.	Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. https://pubmed.ncbi.nlm.nih.gov/15812560/	Br J Cancer.	2005	Volum: 25;92(8): doi: 10.1038/sj.bjc.6602408	7	4.115
CA-6	Suleymanova N, Crudden C, Worrall C, Dricu A , Girnita A, Girnita L	Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. https://pubmed.ncbi.nlm.nih.gov/29137261/	ONCOTARGET	2017	Volume 8(47): DOI 10.2147/OTT.S112842	11	5.168
CA-7	Kanter-Lewensohn L, Girnita L, Girnita A, Dricu A , Olsson G, Leech L, Nilsson G, Hilding A, Wejde J, Brismar K, Larsson O.	Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. https://pubmed.ncbi.nlm.nih.gov/10940491/	Mol Cell Endocrinol.	2000	Volume 25;165 doi: 10.1016/s0303-7207(00)00253-7	6	2.369
	Wang M, Xie Y, Girnita L, Nilsson G, Dricu A , Wejde J, Larsson O.	Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. https://pubmed.ncbi.nlm.nih.gov/9882513/	Exp Cell Res.	1999	Volume 246(1) doi: 10.1006/excr.1998.4280.	8	3.256
CA-8	Zhang J, Dricu A , Sjövall J.	Studies on the relationships between 7 alpha-hydroxylation and the ability of 25- and 27-hydroxycholesterol to suppress the activity of HMG-CoA reductase. https://pubmed.ncbi.nlm.nih.gov/9059514/	Biochim Biophys Acta	1997	Volume 1344(3) doi: 10.1016/s0005-2760(96)00148-8.	8	2.411

CA -9	Carlberg M, Dricu A , Blegen H, Wang M, Hjertman M, Zickert P, Höög A, Larsson O.	Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. https://pubmed.ncbi.nlm.nih.gov/8663239/	J Biol Chem.		Volume 271(29) doi: 10.1074/jbc.271.29.17453	11	8.426
CA -10	Carlberg M, Dricu A , Blegen H, Kass GE, Orrenius S, Larsson O.	Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts. https://pubmed.ncbi.nlm.nih.gov/9006093/	Carcinogenesis.	1996	Volume 17(12) doi: 10.1093/carcin/17.12.2589.	7	3.509

11. The Expression of miR-155-5p and Local Matrix Gla Protein in MeningiomasGheorghe, SR (Gheorghe, Simona Roxana); Marian, C (Marian, Catalin); Tataranu, LG (Tataranu, Ligia Gabriela) [3]; Dricu, A (Dricu, Anica) [4]; Vermeer, C (Vermeer, Cees); Silaghi, CN (Silaghi, Ciprian Nicolae); Craciun, AM (Craciun, Alexandra Marioara). REVISTA ROMANA DE MEDICINA DE LABORATOR. **Volume 29 Issue 3 Page 299-306 DOI 10.2478/rrlm-2021-0020** Co-Autor
12. IN VITRO AND IN VIVO EFFECTS OF Fe₃O₄/SALICYLIC ACID MAGNETIC NANOPARTICLES ON THE HUMAN GLIOBLASTOMA CELLS. 2014, Buteica, SA (Buteica, S. A.) [1]; Mîndrila, I (Mindrila, I.) [1]; Mihaiescu, DE (Mihaiescu, D. E.) [3]; Purcaru, SO (Purcaru, S. O.) [2]; Dricu, A (Dricu, A.) [2]; Nicolicescu, C (Nicolicescu, C.) [4]; Neamtu, J (Neamtu, J.) [1] DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES Volume 9 Issue 3 Page 959-965 Co-Autor
13. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Girmita L, Wang M, Xie Y, Nilsson G, **Dricu A**, Wejde J, Larsson O. Anticancer Drug Des. 2000 Feb;15(1):67-72. PMID: 10888037
14. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Kanter-Lewensohn L, **Dricu A**, Girmita L, Wejde J, Larsson O. Growth Factors. 2000;17(3):193-202. doi: 10.3109/08977190009001068. PMID: 10705577
15. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Kanter-Lewensohn L, **Dricu A**, Wang M, Wejde J, Kiessling R, Larsson O. Melanoma Res. 1998 Oct;8(5):389-97. doi: 10.1097/00008390-199810000-00002. PMID: 9835451
16. Specific and sensitive detection of the EWS/FLI1 fusion protein in Ewing's sarcoma by Western blotting. Wang M, Nilsson G, Carlberg M, **Dricu A**, Wejde J, Kreicbergs A, Larsson O. Virchows Arch. 1998 Feb;432(2):131-4. doi: 10.1007/s004280050146. PMID: 9504857
17. Evidence for protein dolichylation. Hjertman M, Wejde J, **Dricu A**, Carlberg M, Griffiths WJ, Sjövall J, Larsson O. FEBS Lett. 1997 Oct 27;416(3):235-8. doi: 10.1016/s0014-5793(97)01208-8. PMID: 9373159 Free article.

Criteriu îndeplinit:

DA NU

3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)

Criteriul	Standard minim	Realizat (<i>suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI Web of Science Clarivate</i>)
(ISI) Factor cumulat de impact autor principal	10	115,829

Lucrările care sunt luate în considerare pentru calculul sumei factorului cumulat de impact pentru articolele publicate ca autor principal in reviste cotate ISI

Nr. Crt.	Tip Autor (*)	An referință	Factor impact	ISSN	DOI/WOS	Articol ISI Titlu	Jurnal
1	Principal	1997	8.426	0008-5472	WOS:A1997 WF51700037	Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: Role of down-regulation of the insulin like growth factor 1 receptor in induction of apoptosis	CANCER RESEARCH
2	Principal	1997	2.927	0959-6658	10.1093/glycob/7.5.625	Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc	GLYCOBIOLOGY
3	Principal	1999	3.728	0959-6658	10.1093/glycob/9.6.571	Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway	GLYCOBIOLOGY
4	Principal	2004	1.395	0250-7005	WOS:0002227 56700014	A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells	ANTICANCER RESEARCH
5	Principal	2005	3.049	0304-3835	10.1016/j.canlet.2004.10.002	Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation	CANCER LETTERS
6	Principal	2007	3.74	0897-7194	10.1080/08977190600702865	Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro	GROWTH FACTORS

7	Principal	2007	6.44	0950-9232	10.1038/sj.onc.1210037	Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism	ONCOGENE
8	Principal	2007	1.86	0167-594X	10.1007/s11060-007-9417-0	Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells	JOURNAL OF NEURO-ONCOLOGY
9	Principal	2009	2.752	0167-594X	10.1007/s11060-008-9753-8	Growth factor receptors signaling in glioblastoma cells: therapeutic implications	JOURNAL OF NEURO-ONCOLOGY
10	Principal	2010	0.113	1841-6624	WOS:000282599800006	S-Adenosylmethionine - induced cytotoxicity in glioblastoma cells does not affect the Igf-1r methylation	REVISTA ROMANA DE MEDICINA DE LABORATOR
11	Principal	2011	3.214	0167-594X	10.1007/s11060-010-0285-7	Helianthin induces antiproliferative effect on human glioblastoma cells in vitro	JOURNAL OF NEURO-ONCOLOGY
12	Principal	2013	1.219	1537-744X	10.1155/2013/343275	Biobanking in a Constantly Developing Medical World	SCIENTIFIC WORLD JOURNAL
13	Principal	2014	2.339	1422-0067	10.3390/ijms15058169	Cancer Stem Cells: Biological Functions and Therapeutically Targeting	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
14	Principal	2015	1.581	1936-2625	WOS:000361538900016	Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment	INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL

							TAL PATHOLOGY
15	Principal	2015	2.272	1178- 6930	10.2147/OTT. S93843	Epidermal growth factor, latrophilin, and seven transmembrane domain- containing protein 1 marker, a novel angiogenesis marker	ONCOTARGE TS AND THERAPY
16	Principal	2016	1.069	1940- 5901	WOS:0003858 37700028	Temozolomide and targeted therapy against epidermal growth factor receptor in glioma	INTERNATIO NAL JOURNAL OF CLINICAL AND EXPERIMEN TAL MEDICINE
17	Principal	2016	0.000	1428- 2526	10.5114/wo.20 15.56122	New perspectives in glioblastoma antiangiogenic therapy	WSPOLCZES NA ONKOLOGIA - CONTEMPOR ARY ONCOLOGY/ 20
18	Principal	2016	1.706	1936- 2625	WOS:0003866 53400057	Rationale and in vitro efficacy of Ligustrum vulgare hydroalcoholic extract for the treatment of brain tumors	INTERNATIO NAL JOURNAL OF CLINICAL AND EXPERIMEN TAL PATHOLOGY

19	Principal	2016	1.653	1178-6930	10.2147/OTT.S112842	Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis	ONCOTARGETS AND THERAPY
20	Principal	2016	1.791	0973-1482	10.4103/0973-1482.167609	The effect of curcumin on low-passage glioblastoma cells in vitro	JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
21	Principal	2017	1.507	2065-0019	WOS:000413731300018	LIGUSTRUM VULGARE HYDROALCOHOLIC EXTRACT INDUCES APOPTOTIC CELL DEATH IN HUMAN PRIMARY BRAIN TUMOUR CELLS	FARMACIA
22	Principal	2018	3.687	1422-0067	10.3390/ijms19010229	The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
23	Principal	2018	3.974	1471-2598	10.1080/14712598.2018.1445715	Recent challenges with stem cell banking	EXPERT OPINION ON BIOLOGICAL THERAPY
24	Principal	2018	4.122	2045-2322	10.1038/s41598-018-30296-x	Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials	SCIENTIFIC REPORTS
25	Principal	2018	1.412	0034-7752	WOS:000458533800067	coRibavirin-induced Anemia in Patients with Chronic Hepatitis C Virus Infection	REVISTA DE CHIMIE
26	Principal	2017	0.000	1532-4230	10.1080/15321819.2016.1209217	Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1)	Journal of Immunoassay and

						via siRNA-induced cell death in glioblastoma.	Immunochemistry
27	Principal	2018	0.000	1532-4230	10.1080/15321819.2017.1411816	Current and emerging EGFR therapies for glioblastoma	Journal of Immunoassay and Immunochemistry
28	Principal	2019	4.556	1422-0067	10.3390/ijms20194663	Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
29	Principal	2019	1.755	0034-7752	10.37358/RC.19.4.7108	Accuracy of Imaging Investigations in Pancreatic Cancer Diagnosis	REVISTA DE CHIMIE
30	Principal	2019	1.755	0034-7752	10.37358/RC.19.1.6862	In vitro Antineoplastic Activity of Dye Compounds on Human Glioblastoma Cells	REVISTA DE CHIMIE
31	Principal	2019	1.755	0034-7752	10.37358/RC.19.5.7178	The Role of Imaging Techniques in Diagnosing Pancreatic Cancer	REVISTA DE CHIMIE
32	Principal	2019	2.436	2079-6412	10.3390/coatings9100628	Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases	Coatings
33	Principal	2020	0.000	1428-2526	10.5114/wo.2020.94726	Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches	WSPOLCZESNA ONKOLOGIA - CONTEMPORARY ONCOLOGY
34	Principal	2021	6.208	1422-0067	10.3390/ijms202094830	The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

35	Principal	2021	2.751	1792-0981	10.3892/etm.2021.10844	Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments	EXPERIMENTAL AND THERAPEUTIC MEDICINE
36	Principal	2021	6.208	1422-0068	10.3390/ijms22105151	ELTD1-An Emerging Silent Actor in Cancer Drama Play	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
37	Principal	2021	6.208	1422-0067	10.3390/ijms222413211	Transcriptomic Crosstalk between Gliomas and Telencephalic Neural Stem and Progenitor Cells for Defining Heterogeneity and Targeted Signaling Pathways	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
38	Principal	2022	5.6	1422-0067	10.3390/ijms23094602	Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
39	Principal	2022	5.6	1422-0067	10.3390/ijms23137376	Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
40	Principal	2022	5.6	1422-0067	10.3390/ijms23179943	Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
41	Principal	2023	5.6	1422-0067	10.3390/ijms241311110	An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

42						An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
	Principal	2023	5.6	1422-0067	10.3390/cimb45090485		
43						The effect of Azo-dyes on glioblastoma cells in vitro	Saudi J Biol Sci
	Principal	2023	4.4	1319-562X	10.1016/j.sjbs.2023.103599		


Criteriu îndeplinit:

DA NU

4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	6	24

Lucrările care sunt luate în considerare pentru calculul indexului Hirsch (conform Web of Science – Core Collection):



Citations

1. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface - Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. Carlberg, M; Dricu, A; (...); Larsson, O. JOURNAL OF BIOLOGICAL CHEMISTRY . Jul 19 1996 | 271 (29) , pp.17453-17462
 115 Citations

2. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Cosaceanu, D; Budiu, RA; (...); Dricu, A. ONCOGENE . Apr 12 2007 | 26 (17) , pp.2423-2434
 83 Citations

3. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact. Girnita, L; Girnita, A; (...); Larsson, O. CANCER RESEARCH. Sep 15 2000 | 60 (18) , pp.5278-5283
 79 Citations

4.Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27^{Kip1} in melanocytic tumors:: A potential regulatory role of IGF-1 pathway in distribution of p27^{Kip1} between different cyclins. Kanter-Lewensohn, L; Dricu, A; (...); Larsson, O. GROWTH FACTORS 2000 | 17 (3) , pp.193-202

58 Citations

5.Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: Role of down-regulation of the insulin like growth factor 1 receptor in induction of apoptosis. Dricu, A; Carlberg, M; (...); Larsson, O. CANCER RESEARCH Feb 1 1997 | 57 (3) , pp.543-548

58 Citations

6.Cancer Stem Cells: Biological Functions and Therapeutically Targeting. Ciurea, ME; Georgescu, AM; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. May 2014 | 15 (5) , pp.8169-8185

54 Citations

7. Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Dricu, A; Wang, M; (...); Larsson, O. GLYCOBIOLOGY Jul 1997 | 7 (5) , pp.625-633

51 Citations

8. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Girnita, L; Wang, M; (...); Larsson, O. ANTI-CANCER DRUG DESIGN. Feb 2000 | 15 (1) , pp.67-72

49 Citations

9. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Kanter-Lewensohn, L; Girnita, L; (...); Larsson, O. MOLECULAR AND CELLULAR ENDOCRINOLOGY . Jul 25 2000 | 165 (1-2) , pp.131-137

46 Citations

10.Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Kanter-Lewensohn, L; Dricu, A; (...); Larsson, O. MELANOMA RESEARCH Oct 1998 | 8 (5) , pp.389-397

41 Citations

11. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+regulatory T cells. Budi, RA; Diaconu, I; (...); Vlad, AM. DISEASE MODELS & MECHANISMS Nov-dec 2009 | 2 (11-12) , pp.593-603

40 Citations

12. Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts Carlberg, M; Dricu, A; (...); Larsson, O. CARCINOGENESIS Dec 1996 | 17 (12) , pp.2589-2596

32 Citations

13.Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Popescu, AM; Alexandru, O; (...); Dricu, A. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2015 | 8 (7) , pp.7825-7837

31 Citations

14. Biobanking in a Constantly Developing Medical World. Artene, SA; Ciurea, ME; (...); Dricu, A. SCIENTIFIC WORLD JOURNAL 2013 |

31 Citations

15. Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Dricu, A; Kanter, L; (...); Larsson, O. GLYCOBIOLOGY Jun 1999 | 9 (6) , pp.571-579

31 Citations

16. **Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation.** Cosaceanu, D; Carapancea, M; (...); Dricu, A. CANCER LETTERS. May 26 2005 | 222 (2) , pp.173-181
30 Citations
17. **Growth factor receptors signaling in glioblastoma cells: therapeutic implications.** Carapancea, M; Alexandru, O; (...); Dricu, A. JOURNAL OF NEURO-ONCOLOGY Apr 2009 | 92 (2) , pp.137-147
29 Citations
18. **Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival.** Catrina, SB; Lewitt, M; (...); Brismar, K. BRITISH JOURNAL OF CANCER. Apr 25 2005 | 92 (8) , pp.1467-1474
29 Citations
19. **Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.** Carapancea, M; Cosaceanu, D; (...); Dricu, A. JOURNAL OF NEURO-ONCOLOGY Dec 2007 | 85 (3) , pp.245-254
28 Citations
20. **New perspectives in glioblastoma antiangiogenic therapy.** Journal information. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY Popescu, AM; Purcaru, SO; (...); Dricu, A. 2016 | 20 (2) , pp.109-118
27 Citations
21. **Evidence for protein dolichylation.** Hjertman, M; Wejde, J; (...); Larsson, O. FEBS LETTERS. Oct 27 1997 | 416 (3) , pp.235-238
26 Citations
22. **Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines *in vitro*.** Cosaceanu, D; Carapancea, M; (...); Dricu, A. GROWTH FACTORS 2007 | 25 (1) , pp.1-8
25 Citations
23. **Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.** Wang, M; Xie, YT; (...); Larsson, O. EXPERIMENTAL CELL RESEARCH Jan 10 1999 | 246 (1) , pp.38-46
25 Citations
24. **Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches.** Alexandru, O; Horescu, C; (...); Dricu, A WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY 2020 | 24 (1) , pp.55-66
24 Citations
25. **Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker.** Serban, F; Artene, SA; (...); Dricu, A. ONCOTARGETS AND THERAPY 2015 | 8 , pp.3767-3774
21 Citations
26. **Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials.** Artene, SA; Turcu-Stiolica, A; (...); Dricu, A. SCIENTIFIC REPORTS. Aug 7 2018 | 8
18 Citations
27. **Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.** Alexandru, O; Sevastre, AS; (...); Dricu, A INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Oct 2019 | 20 (19)

15 Citations

28. The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer. Purcaru, OS; Artene, SA; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES May 2021 | 22 (9)

14 Citations

29. Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis. Silosi, I; Boldeanu, L; (...); Silosi, CA. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Jun 2017 | 18 (6)

14 Citations

30. Studies on the relationships between 7 alpha-hydroxylation and the ability of 25- and 27-hydroxycholesterol to suppress the activity of HMG-CoA reductase. Zhang, J; Dricu, A and Sjovall, J. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM. Feb 18 1997 | 1344 (3) , pp.241-249

14 Citations

31. Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases. Sevastre, AS; Horescu, C; (...); Dricu, A. COATINGS Oct 2019 | 9 (10)

13 Citations

32. The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma. Alexandru, O; Purcaru, SO; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Jan 2018 | 19 (1)

13 Citations

33. Specific and sensitive detection of the EWS/FLI1 fusion protein in Ewing's sarcoma by Western blotting. VIRCHOWS ARCHIV Wang, M; Nilsson, G; (...); Larsson, O

Feb 1998 | 432 (2) , pp.131-134

12 Citations

34. Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). Sevastre, AS; Costachi, A; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Dec 2021 | 22 (6)

11 Citations

35. Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. Suleymanova, N; Crudden, C; (...); Girnita, L. LONCOTARGET Oct 10 2017 | 8 (47) , pp.82256-82267

11 Citations

36. Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer. Rodriguez, SMB; Staicu, GA; (...); Tataranu, LG. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. May 2022 | 23 (9)

10 Citations

37. The effect of curcumin on low-passage glioblastoma cells in vitro. Alexandru, O; Georgescu, AM; (...); Dricu, A. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS. Apr-jun 2016 | 12 (2) , pp.1025-1032

8 Citations

38. Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. Alexandru, O; Dragutescu, L; (...); Dricu, A. JOURNAL OF NEURO-ONCOLOGY

Mar 2011 | 102 (1) , pp.9-18

8 Citations

39. **A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. Dricu, A; Sergiu-Bogdan, C; (...); Andersson, LC. ANTICANCER RESEARCH May-jun 2004 | 24 (3A) , pp.1427-1432**

8 Citations

40. **LIGUSTRUM VULGARE HYDROALCOHOLIC EXTRACT INDUCES APOPTOTIC CELL DEATH IN HUMAN PRIMARY BRAIN TUMOUR CELLSTataranu, LG; Georgescu, AM; (...); Dricu, A. FARMACIA Sep-oct 2017 | 65 (5) , pp.766-771**

7 Citations

41. **ELTD1-An Emerging Silent Actor in Cancer Drama Play. Sevastre, AS; Buzatu, IM; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESMay 2021 | 22 (10)**

6 Citations

42. **Recent challenges with stem cell banking. Dricu, A. EXPERT OPINION ON BIOLOGICAL THERAPY 2018 | 18 (4) , pp.355-358**

5 Citations

43. **Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Artene, SA; Turcu-Stiolica, A; (...); Dricu, A. ONCOTARGETS AND THERAPY. 2016 | 9 , pp.6669-6676**

5 Citations

44. **Temozolomide and targeted therapy against epidermal growth factor receptor in glioma. Daianu, O; Georgescu, AM; (...); Dricu, A. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE. 2016 | 9 (8) , pp.15249-15261**

5 Citations

45. **In vitro Antineoplastic Activity of Dye Compounds on Human Glioblastoma Cells. Alexandru, O; Georgescu, AM; (...); Dricu, A. REVISTA DE CHIMIE Jan 2019 | 70 (1) , pp.112-117**

3 Citations

46. **Rationale and in vitro efficacy of Ligustrum vulgare hydroalcoholic extract for the treatment of brain tumors. Mogosanu, GD; Buteica, SA; (...); Dricu, A. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2016 | 9 (8) , pp.8286-8296**

3 Citations

47. **IN VITRO AND IN VIVO EFFECTS OF Fe₃O₄/SALICYLIC ACID MAGNETIC NANOPARTICLES ON THE HUMAN GLIOBLASTOMA CELLS. Buteica, SA; Mîndrila, I; (...); Neamtu, J. DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES Jul-sep 2014 | 9 (3) , pp.959-965**

3 Citations

48. **An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Rodriguez, SMB; Kamel, A; (...); Tataranu, LG. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESJul 2023 | 24 (13)**

2 Citations

49. **The effect of Azo-dyes on glioblastoma cells in vitro. Sevastre, AS; Baloi, C; (...); Dricu, A. SAUDI JOURNAL OF BIOLOGICAL SCIENCES Mar 2023 | Feb 2023 (Early Access) |**

30 (3)

2 Citations

50. Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy. Sevastre, AS; Manea, EV; (...); Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Sep 2022 | 23 (17)

2 Citations

51. Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities. Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Jul 2022 | 23 (13)

2 Citations

52. Transcriptomic Crosstalk between Gliomas and Telencephalic Neural Stem and Progenitor Cells for Defining Heterogeneity and Targeted Signaling Pathways. Deleanu, R; Ceafalan, LC and Dricu, A. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Dec 2021 | 22 (24)

2 Citations

53. The relationship between cognitive function, tumour histology and surgical treatment in patients with primary brain tumours. Alexandru, O; Ciubotaru, V; (...); Dricu, A 18th Meeting of the European-Neurological-Society Jun 2008 | 255 , pp.154-154

2 Citations

54. S-Adenosylmethionine - induced cytotoxicity in glioblastoma cells does not affect the Igf-1r methylation. REVISTA ROMANA DE MEDICINA DE LABORATOR Ola, R; Scorei, ID; (...); Dricu, A Sep 2010 | 18 (3) , pp.51-59

1 Citation

55. A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis. Semenescu, LE; Tataranu, LG; (...); Kamel, A. BIOMEDICINES. Sep 2023 | 11 (9)

0 Citation

56. An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases. Semenescu, LE; Kamel, A; (...); Tataranu, LG. CURRENT ISSUES IN MOLECULAR BIOLOGY Sep 2023 | 45 (9) , pp.7680-7704

0 Citation

57. The Expression of miR-155-5p and Local Matrix Gla Protein in Meningiomas Gheorghe, SR; Marian, C; (...); Craciun, AM. REVISTA ROMANA DE MEDICINA DE LABORATOR Jul 2021 | 29 (3) , pp.299-306

0 Citation

58. The Role of Imaging Techniques in Diagnosing Pancreatic Cancer. Sas, L; Taisescu, O; (...); Sas, T REVISTA DE CHIMIE May 2019 | 70 (5) , pp.1608-1614

0 Citation

59. Accuracy of Imaging Investigations in Pancreatic Cancer Diagnosis Sas, L; Taisescu, O; (...); Taisescu, CI. REVISTA DE CHIMIE Apr 2019 | 70 (4) , pp.1272-1277

0 Citation

60. coRibavirin-induced Anemia in Patients with Chronic Hepatitis C Virus Infection. Taisescu, CI; Demetrian, A; (...); Taisescu, O. REVISTA DE CHIMIE Dec 2018 | 69 (12) , pp.3648-3652

0 Citation

61. **The correlation between MMR gene expression MSH2/MSH6 and VEGF A/VEGF B in gastro-esophageal cancer. Dracea, A; Danciulescu, M; (...); Ioana, M42nd European-Society-for-Medical-Oncology Congress (ESMO)ANNALS OF ONCOLOGY Sep 2017 | 28**
 0_ Citation
62. **COST-EFFECTIVENESS ANALYSIS OF TREATMENT FOR RECURRENT MALIGNANT GLIOMA IN ROMANIA. Turcu-Stolica, A; Artene, S; (...); Dricu, AVALUE IN HEALTH Nov 2016 | 19 (7) , pp.A736-A736**
 0_ Citation
63. **Surgical Management of Non-functioning Pituitary Adenomas. Ciubotaru, V; Tataranu, L; (...); Dricu, AAnnual Meeting of the European-Association-of-Neurosurgical-Societies (EANS)2012 | PAPERS PRESENTED AT THE EANS ANNUAL MEETING , pp.53-59**
 0_ Citation
64. **The level of circulating endothelial progenitor cells is increased in glioblastoma patientsAlexandru, O; Georgescu, AM; (...); Dricu, A13th Congress of the European-Federation-of-Neurological-SocietiesEUROPEAN JOURNAL OF NEUROLOGY Oct 2009 | 16 , pp.575-575**
 0_ Citation
65. **Antiproliferative effect of helianthine on human glioblastoma cells in vitro. Alexandru, O; Dragutescu, LE; (...); Dricu, A19th Meeting of the European-Neurological-SocietyJOURNAL OF NEUROLOGY Jun 2009 | 256 , pp.S228-S228**
 0_ Citation
66. **TYROSINE KINASE RECEPTOR SIGNALING IN GLIOBLASTOMA CELLS: THERAPEUTIC IMPLICATIONS. Alexandru, O; Carapancea, M; (...); Dricu, A. 8th Congress of the European-Association-for-Neuro-Oncology (EANO) NEURO-ONCOLOGY Dec 2008 | 10 (6) , pp.1113-1113**
 0_ Citation
67. **Co-inhibition of IGF-1R and PDGFR synergistically inhibit proliferation in GB cells and induce radiosensitivity in JNK-expressing glioblastoma cells. Carapancea, M and Dricu, A. CANCER RESEARCH Apr 2006 |**
 0_ Citation
68. **Expression of tumor antigens MUC1 and cyclin B1 in chronic inflammatory lesions (endometriosis) and in ovarian epithelial tumors. Vlad, AM; Diaconu, I; (...); Finn, OJ. Annual Meeting of the American-Association-of-Immunologists JOURNAL OF IMMUNOLOGY Apr 1 2006 | 176 , pp.S267-S267**
 0_ Citation

Criteriu îndeplinit:

DA NU

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

Data

17-02-2024

Semnătura candidatului

Note asupra metodei de calcul:

1. va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science Clarivate, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);
2. o revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
3. autorul/autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
 - a. primul autor;
 - b. autorul corespondent;
 - c. alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent;
 - d. ultimul autor.
4. factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI;
5. vor fi incluse articole originale și reviews; în cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații în extenso (nu rezumate).